Two vaccine doses boost antibody levels in the airways after COVID-19

Two vaccine doses boost antibody levels in the airways after COVID-19
Systemic antibody responses, inflammation markers and other clinical parameters in relation to COVID-19 severity during acute disease. (A) Plasma IgG and IgA responses (n=19 for mild, n=58 for moderate, n=58 for severe and n=12 for fatal) against N, S and RBD are shown together with the levels of (B) C-reactive protein and the neutrophil-lymphocyte ratio as a measure of systemic inflammation and with (C) the levels of lymphocytes, monocytes and neutrophils. Black lines indicate medians. Differences were assessed using Kruskal -Wallis with Dunn’s multiple comparisons test and considered statistically significant at p<0.05. ** p<0.01, *** p<0.001, **** p<0.0001. The dashed lines indicate the normal thresholds or range values. (D) Correlation matrix summarizing the interrelationship observed between the clinical parameters, inflammation markers, blood corpuscles and data from systemic antibody levels measured during acute disease as indicated. The P and R values (Spearman) are shown separately in the mirrored halves of the matrix and have been color-coded as indicated. Credit: DOI: 10.1172/jci.insight.151463

Antibodies in the airways quickly wane after SARS-CoV-2 infection, but vaccination results in a strong increase in antibody levels, especially after two doses, according to a new study from Karolinska Institutet in Sweden published in the journal JCI Insight. The results suggest that having a second dose of vaccine also after recovering from COVID-19 may be important for protecting against re-infection and to prevent transmission.

"What makes the study unique is that we have looked at samples from both and airways, which has given us new knowledge of the local immune response where the virus infects," says the study's co-last author Anna Smed-Sörensen, docent and research group leader at the Department of Medicine, Solna, Karolinska Institutet. "Since it is more difficult to sample the airways, we know much less about antibody levels there than in the blood."

In their study, the researchers examined how the levels and durability of the antibodies to SARS-CoV-2 differed between individuals who had mild to severe COVID-19. 147 patients were recruited in March to May 2020 and monitored for up to eight months after infection. In 20 of the patients, they also studied antibody levels after vaccination (with the AstraZeneca, Pfizer-BioNTech or Moderna vaccine) and compared the results with a control group that had not previously had COVID-19.

Their results show that individuals who underwent more severe COVID-19 disease had higher antibody levels upon recovery compared to individuals with mild disease. The antibodies in the blood remained at measurable levels for at least eight months, while those in the airways (e.g. the nose) were short-lived and disappeared already after three months.

"The positive news is that the antibodies quickly returned after vaccination in those who previously had COVID-19, not only in the blood but also in the airways," says Dr. Smed-Sörensen. "We found that the antibody levels in the airways after two doses of vaccine were often even higher than they were during the course of the disease. People who had not had COVID-19 before vaccination had much lower or undetectable levels."

In the COVID-19 patients, the second vaccine dose did not have such a strong effect on the antibody levels in the blood. This is in line with earlier studies on the antibody response in the blood where people who previously had COVID-19 showed a strong increase in antibodies after the first dose, but only a small increase—if any—after the second.

"Our results demonstrate that to only study blood does not reflect the antibody levels in the respiratory tract, which likely play a major part in neutralizing the virus locally," says co-last author Karin Loré, professor at the Department of Medicine, Solna, Karolinska Institutet. "Completing the vaccination with a second dose may therefore be important for achieving optimal immune responses and reducing the spread of infection between individuals."

The level of required for protection against infection remains unknown, as well as whether the rapid drop in in the airways allows for re-infection. The researchers will now continue to analyze samples from additional longitudinal time points and examine the inflammatory environment in the during infection, convalescence and after vaccination.

The study was financed by the Swedish Research Council, the Swedish Heart-Lung Foundation and the Bill & Melinda Gates Foundation, as well as the Knut and Alice Wallenberg Foundation through SciLifeLab and Karolinska Institutet. There are no reported conflicts of interest.


Explore further

Greater, broader SARS-CoV-2 neutralizing antibodies with third dose of vaccine

More information: Alberto Cagigi et al, Airway antibodies emerge according to COVID-19 severity and wane rapidly but reappear after SARS-CoV-2 vaccination, JCI Insight (2021). DOI: 10.1172/jci.insight.151463
Citation: Two vaccine doses boost antibody levels in the airways after COVID-19 (2021, October 20) retrieved 2 December 2021 from https://medicalxpress.com/news/2021-10-vaccine-doses-boost-antibody-airways.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
206 shares

Feedback to editors